Orexin-A vs Elamipretide
Head-to-head comparison of Orexin-A (Hypocretin-1 (Orexin-A)) and Elamipretide (Elamipretide (MTP-131, SS-31)) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Orexin-A | Elamipretide |
|---|---|---|
| Category | Cognitive Enhancement | Muscle & Performance |
| Full Name | Hypocretin-1 (Orexin-A) | Elamipretide (MTP-131, SS-31) |
| Molecular Weight | 3562 Da | 639.8 Da |
| Half-Life | Minutes to <1 hour | 1-4 hours |
| Amino Acids | 33 | 4 |
| Typical Dose | Research-only; no validated human dose | 0.01-0.25 mg/kg/day |
| Route | Intracerebroventricular/Intranasal | Subcutaneous/Intravenous |
| Purity | ≥98% | ≥98% |
| Studies Count | 42 | 120 |
| Research Status | Pre-clinical | Clinical |
Orexin-A Benefits
- ✓wakefulness
- ✓attention
- ✓memory consolidation
- ✓fatigue resistance
Elamipretide Benefits
- ✓mitochondrial protection
- ✓reduced oxidative stress
- ✓improved fatigue resistance
- ✓may support exercise tolerance
Orexin-A Dosing
Research-only i.c.v. microgram/nanomolar studies|intranasal experimental use|no established human protocol
Elamipretide Dosing
0.01-0.25 mg/kg/day SC (clinical research)|daily dosing in trials|alternative IV protocols in some studies
Orexin-A Side Effects
- ⚠insomnia
- ⚠headache
- ⚠blood pressure changes
Elamipretide Side Effects
- ⚠nausea
- ⚠injection-site reactions
- ⚠diarrhea
- ⚠headache
Research Overview
Orexin-A
Preclinical studies link orexin signaling to arousal, learning, and memory consolidation, making orexin-A a candidate for cognition-related research. It is not an approved cognitive enhancer and remains an experimental peptide.
Elamipretide
Clinical and translational studies show elamipretide can improve mitochondrial function and some functional endpoints in mitochondrial disorders. Skeletal muscle research suggests benefits are driven by energy metabolism rather than direct muscle-building effects.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.